Navigation Links
Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Date:4/13/2009

F have been reported with TNF blockers. Cases of CHF in patients with known cardiovascular risk factors have been observed with SIMPONI. SIMPONI should be used with caution in patients with heart failure and should be discontinued if new or worsening symptoms of heart failure appear. TNF-blocking agents, including SIMPONI, have been associated in rare cases with demyelinating disease. The benefits and risks of anti-TNF treatment should be carefully considered before initiation of SIMPONI therapy in patients with pre-existing or recent onset of demyelinating disorders. Treatment with SIMPONI may result in the formation of auto-antibodies and, rarely, in the development of a lupus-like syndrome. Women of childbearing potential must use adequate contraception to prevent pregnancy and continue its use for at least 6 months after the last SIMPONI treatment.

The most common adverse drug reaction reported from clinical trials was upper respiratory tract infection (7.2 percent of SIMPONI-treated patients compared with 5.8 percent in control-treated patients). In controlled Phase 3 trials through Week 16 in RA, PsA and AS, 5.8 percent of SIMPONI treated patients had injection site reactions compared with 2.2 percent in control-treated patients. The majority of the injection site reactions were mild and moderate, and the most frequent manifestation was injection site erythema.

About Centocor Ortho Biotech Inc.

Centocor Ortho Biotech Inc. redefines the standard of care in immunology, nephrology, and oncology. The company was created when Ortho Biotech Inc. merged into Centocor, Inc., and Centocor, Inc. was renamed Centocor Ortho Biotech Inc. Built upon a pioneering history, Centocor Ortho Biotech Inc. harnesses innovations in large-molecule and small-molecule research to create important new therapeutic options. Beyond its innovative medicines, Centocor Ortho Biotech is at the forefront of developi
'/>"/>

SOURCE Centocor Ortho Biotech Inc.; Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Healthplace America Engages Robert A. Yungk to Provide Services as Chief Strategy Officer
2. Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide
3. MedTrust Online and Scottsdale Clinical Research Institute at Scottsdale Healthcare Announce Collaboration to Provide Cutting Edge Technology to Improve Patient Care
4. Siemens Healthcare Announces Planned Collaboration with Harris Corporation
5. Kibow Biotech, Inc. Launches Breakthrough Probiotic Dietary Supplement for Kidney Health in USA and Canada
6. Midwest Research Institute Expands in Kansas to Support Regional Economic Development in Animal Health, Biosecurity, and Bioenergy Sectors
7. Health Care Innovations and Opportunities Attract Attendees from 40 Countries and Delegations from 12 to 6th Annual World Health Care Congress
8. Nearly 70 Percent of Health Professionals Support Biotechnologys Use in Food Products
9. The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health
10. MMR and Dancing Paws to Participate in Joint Sales Effort to Provide Personal Health Records for Pets
11. Hoosiers Work for Health Highlights Impact of Medical Research and Innovation on Indiana Economy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 ... investment research firm, announces the initiation of ... French biopharmaceutical company developing and marketing products ... indications.      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) ... report examining the investment merits of BioAlliance ...
(Date:6/18/2013)... ZIONA, Israel , June 18, ... of complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative ... systems, announced today that the company has been granted a ... is indicated in the US and Europe ... US Patent number 8,410,176 B2 is titled Intermediate ...
(Date:6/18/2013)... 18, 2013 Research ... the addition of the report " DNA ... to their offering.      (Logo: ... basics of human genome variations, development of ... and small sequencers are described as well ...
(Date:6/18/2013)... Scottsdale, AZ (PRWEB) June 18, 2013 ... telemedicine services MeMD, Inc proudly announces the release ... Revolutionizing Health and Fitness ". , MeMD's goal ... the ever-changing landscape of Health 2.0, Health 3.0 ... that will likely transform medical care and the ...
Breaking Biology Technology:Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol" 2DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2MeMD, Inc Releases Infographic Featuring the Top Eight Technologies that are Revolutionizing Health and Fitness Today 2
... Sept. 18 /PRNewswire-FirstCall/-- Biodel Inc. (Nasdaq:,BIOD) today ... program,at the 43rd Scientific Sessions of the ... VIAject(TM) Phase II meal study data ... entitled, "Pharmacokinetics and pharmacodynamics of,insulin VIAject(TM), insulin ...
... Advantage of ... after HIV Infection, RICHMOND, Calif., Sept. 18 /PRNewswire-FirstCall/ ... the presentation of data,demonstrating that human CD4 T-cells can ... zinc finger DNA-binding protein nucleases,(ZFN(TM)) and preferentially survive and ...
... the Increasing Global Need for Genzyme Products, CAMBRIDGE, ... today broke ground on a significant expansion of its,flagship ... project is focused on adding space for manufacturing support,functions, ... The expansion was marked by a ceremony featuring ...
Cached Biology Technology:Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 2Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 3Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 2Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 3Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 4Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 5Genzyme Begins Major Expansion of Boston Manufacturing Facility 2Genzyme Begins Major Expansion of Boston Manufacturing Facility 3Genzyme Begins Major Expansion of Boston Manufacturing Facility 4Genzyme Begins Major Expansion of Boston Manufacturing Facility 5
(Date:6/18/2013)... of DNA and this modification can occur in ... now, scientists believed that this epigenetic phenomenon actively ... team of researchers from the University of Geneva ... at the Faculty of Medicine, reveals that this ... methylation may play both a passive and active ...
(Date:6/18/2013)... of Adelaide shows that weight gain and increased head size ... a higher IQ at early school age. , The study was ... from more than 13,800 children who were born full-term. , The ... that babies who put on 40% of their birthweight in the ... time they were six years of age, compared with babies who ...
(Date:6/17/2013)... with central nervous system infections may well be suffering ... to a study to be published in mBio ... for Microbiology. Researchers have detected the virus in spinal ... nervous system infections of unknown cause, and in an ... and poultry, suggesting animals may serve as reservoirs for ...
Breaking Biology News(10 mins):The secret of DNA methylation 2IQ link to baby's weight gain in first month 2New virus discovered in patients with central nervous system infections 2New virus discovered in patients with central nervous system infections 3
... more than 10 years of cooperative research on ... the USDA Forest Service,s Pacific Southwest Research Station ... Phytophthora ramorum : A Summary of the Literature." ... of topics, including a history of sudden oak ...
... Vegas, NV (Dec. 24, 2010) - Three weeks of ... heart attack returned microRNA activity close to their pre-event ... studied, just six were attributed to exerting the majority ... study four microRNA optimally regulated by Longevinex and ...
... An expert working group of the International ... Clinical Chemistry and Laboratory Medicine (IFCC) has released ... of bone turnover markers (BTMs) in fracture risk ... it identifies research priorities and recommends that specific ...
Cached Biology News:Comprehensive report on sudden oak death 2Longevinex exerts greater influence over genes than resveratrol 2Longevinex exerts greater influence over genes than resveratrol 3Standardized protocols would greatly enhance clinical and research potential of BTMs 2
... Immunogen KLH-conjugated, synthetic ... 47-66 (PAEV-GPGAVGERTPRKKEPP) of human BRAF-HDAC ... (BHC110/LSD1). Quality Assurance ... Stability 2 years ...
Request Info...
...
...
Biology Products: